Skip to content

Driving Biopharmaceutical Advancements of Naturally Derived and Evidence Based Products

Who We Are

Avicanna Is a Commercial-Stage International Biopharmaceutical Company Focused on the Advancement and Commercialization of Evidence-Based Cannabinoid-Based Products for the Global Medical and Pharmaceutical Market Segments
Avicanna is a commercial-stage international biopharmaceutical company focused on the advancement and commercialization of cannabinoid-based products and formulations for the global medical and pharmaceutical market segments. Avicanna has an established scientific platform including R&D and clinical development leading to the commercialization of more than thirty proprietary, evidence-based finished products and supporting four commercial stage business pillars

Corporate Overview

An International Biopharmaceutical Strategy

First pharmaceutical marketing authorization (Trunerox) 

2023 revenue of $16.8M, representing 314% growth year over year 

Active and commercial business pillars including Medical Cannabis Products, Medical Cannabis Care, Pharmaceutical Products, and Active Pharmaceutical Ingredients.  

Addressing a global market opportunity – 20+ countries



Leading Scientific Platform and Intellectual Property Portfolio

Established industry leading R&D and scientific infrastructure     

JLABS @Johnson and Johnson incubated – at MaRS

30+ commercialized proprietary SKUs – From R&Ds to international commercial channels

Proprietary and indication specific pharmaceutical pipeline

Research and clinical partnerships with leading academic and clinical institutions 

Medical affairs and clinical development platform

Intellectual Property and Brands Owned by Avicanna

Medical Cannabis Products and RHO Phyto – Commercial  

Medical Cannabis Pharmacy Platform – Launched August

Pharmaceutical Products – In development and registration stages 

Active Pharmaceutical Ingredients – Aureus Santa Marta 

Four Commercial Stage Business Pillars

Avicanna’s scientific platform has resulted in 30+ proprietary formulations and commercial products
Including medical cannabis, medical cannabis care, Pharmaceutical products and active pharmaceutical ingredients
Medical Cannabis Care Platform

Medical Cannabis Products

Pharmaceutical Products

Active Pharmaceutical Ingredients

Industry Leading Scientific Platform

Setting the Standard in the Cannabinoid Industry with Advanced and Evidence-Based Products

Scientific Platform

R&D Platform Delivering Advanced and Evidence-Based Cannabinoid Products 

R&D headquarters in Toronto, Canada with drug development pipeline including sustained release tablets, transdermal patches and nano-particle formulations. 


Proprietary Commercial Products




Canadian Government Research Grants Awarded Since 2020


Pending Patents


Health Canada Cannabis
Research Licenses
to Avicanna
or Institutional Collaborators

World-class Institutional Collaborations

R&D and Clinical Partnerships Over the Past 6 Years

World-Class Institutional Collaborations

20+ R&D, Pre-Clinical Studies and Collaborations with Canada’s Leading Institutions since 2017
Majority of the research has been conducted in Canada through 4 Health Canada cannabis R&D licenses issued to Avicanna and its academic collaborators.

Clinical Development

Setting the Standard in the Cannabinoid Industry on Advanced and Evidence-Based Products


Products & Pipeline

Serving the Global Marketplace with Proprietary Advanced Cannabinoid-Based Products